IKNA (Ikena) Pangali Forward P/E

Simbol resmi perusahaan Ikena Oncology (IKNA)

Ikena Oncology, Inc. (IKNA) relies on patent protection for its targeted therapy developments, where success is driven by the precision of clinical data. The company's forward P/E clearly demonstrates the valuation dynamics, with 0.00 representing the current level of this metric. Management is betting on biomarkers for precision treatment, while a solid liquidity reserve ensures financial stability as the company explores new strategic business development scenarios.

ikenaoncology.com - Pangali Forward P/E IKNA (periode 04.07.2022 - 09.08.2025)

Ringkesan rincian data analitis Ikena Oncology, Inc. (IKNA)

Analisis dhasar perusahaan:IKNA Ikena Oncology Inc.
Produk merek Ikena

Ikena Oncology, Inc. (IKNA) develops targeted cancer therapies within a protected U.S. scientific environment, which minimizes external business risks. The ratio of the current share price to projected earnings for the coming year, represented by the company's forward P/E NTM, allows for an assessment of market expectations and the identification of potential valuation discrepancies relative to the asset's future profitability.

Analisis perusahaan pesaing

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Bio (BCAX) - Rega marang bathi mangsa ngarep|Personalis Corp - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Systems, Inc. DCTH|Prakiraan rega marang bathi YMAB (Y-mAbs Corp)|Pangali Forward P/E Aura Bio (AURA)|Pangali Forward P/E CADL (Candel Therapeutics Inc.)|ARAY - Prakiraan rega marang bathi|SLS - Rega marang bathi mangsa ngarep|Actuate Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|CTOR: Pangali Forward P/E|TuHURA (HURA) - Pangali Forward P/E|TARA (Protara Therapeutics Inc) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|TCRX (TScan) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT - Prakiraan rega marang bathi|CEL-SCI - Pangali Forward P/E|OSTX - Pangali Forward P/E|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|ARTV - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ANL|Rega marang bathi mangsa ngarep VERU|Pangali Forward P/E TPST|XLO: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E RENB (Renovaro Inc.)|Mural Bio (MURA) - Rasio prakiraan rega marang bathi|Kairos Pharma Ltd - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake OKUR|CytoMed Therapeutics Limited (GDTC) - Rega marang bathi mangsa ngarep|CRIS - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi APLM|Tharimmune (THAR) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ADVB (Advanced Biomed Inc.)|Genprex - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Prakiraan rega marang bathi|Xenetic Bio - Pangali Forward P/E|SLRX - Pangali Forward P/E|PPBT: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep AONC|BGNE (BeiGene Ltd) - Pangali Forward P/E|CKPT (Checkpoint Therapeutics, Inc) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E ELEV|Prakiraan rega marang bathi iCAD Corp ICAD|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E